Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
暂无分享,去创建一个
S. Dewilde | Jacqueline A Palace | G. Bassez | R. Mantegazza | M. Larkin | S. Berrih-Aknin | F. Saccà | H. Murai | S. Muppidi | Andreas Meisel | S. Chiroli | Mf Janssen | J. Beauchamp | K. Claeys | S. Paci | Glenn Philips | Casey Quinn | L. Day | A. Meisel
[1] Jonas Jacobi,et al. Burden of disease in myasthenia gravis: taking the patient’s perspective , 2021, Journal of Neurology.
[2] R. Mantegazza,et al. Estimation of myasthenia gravis prevalence in Italy using real-world data , 2021, Journal of the Neurological Sciences.
[3] S. Dewilde,et al. Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG) , 2021, BMJ Open.
[4] B. Soliven,et al. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations , 2021, Journal of clinical medicine.
[5] M. Leone,et al. The epidemiology of myasthenia gravis , 2021, Journal of medicine and life.
[6] H. Andersen,et al. Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis , 2020, Frontiers in Neurology.
[7] M. Lipowska,et al. Determinants of Quality of Life in Myasthenia Gravis Patients , 2020, Frontiers in Neurology.
[8] G. Cutter,et al. Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States , 2020, Journal of clinical neuromuscular disease.
[9] B. K. Vitturi,et al. Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis , 2020, Neurological Sciences.
[10] B. Roy,et al. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry – The EXPLORE-MG registry , 2020, Journal of the Neurological Sciences.
[11] G. Bonsel,et al. Does the EQ-5D-5L benefit from extension with a cognitive domain: Testing a multi-criteria psychometric strategy in trauma patients , 2020, Quality of Life Research.
[12] L. Prieto-Pinto,et al. Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature. , 2019, Intractable & rare diseases research.
[13] G. Cutter,et al. Cross‐sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment , 2019, Muscle & nerve.
[14] J. Brazier,et al. Selecting Bolt-On Dimensions for the EQ-5D: Examining Their Contribution to Health-Related Quality of Life. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] M. Hoogendoorn,et al. Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] M. Jo,et al. Exploratory Study of Dimensions of Health-related Quality of Life in the General Population of South Korea , 2017, Journal of preventive medicine and public health = Yebang Uihakhoe chi.
[17] John Brazier,et al. The Use of Health State Utility Values in Decision Models , 2017, PharmacoEconomics.
[18] M. Conaway,et al. International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r , 2016, Muscle & nerve.
[19] U. Grittner,et al. Fatigue in myasthenia gravis: risk factors and impact on quality of life , 2016, Brain and behavior.
[20] J. Verschuuren,et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts , 2015, Health and Quality of Life Outcomes.
[21] Katie Brittain,et al. The effectiveness of collaborative care for people with memory problems in primary care: results of the CAREDEM case management modelling and feasibility study. , 2014, Health technology assessment.
[22] A. F. Stern. The hospital anxiety and depression scale. , 2014, Occupational medicine.
[23] J. Brazier,et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.
[24] K. Boye,et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] T. Kohlmann,et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] M. Conaway,et al. MG‐ADL: Still a relevant outcome measure , 2011, Muscle & nerve.
[27] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[28] J. Kugler,et al. Quality of life and life circumstances in German myasthenia gravis patients , 2010, Health and quality of life outcomes.
[29] M. Conaway,et al. Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravis , 2008, Muscle & nerve.
[30] Monica Milani,et al. Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.
[31] T. T. Haug,et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.
[32] P. Tonali,et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements , 2001, Neurological Sciences.
[33] D B Sanders,et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.
[34] G. Wolfe,et al. Myasthenia gravis activities of daily living profile , 1999, Neurology.
[35] L. Phillips. The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.
[36] R. Snaith,et al. The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.